$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000162828019013718 Filed on November 07, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q3
Revenue	$62.90M	$60.85M	$21.69M
YoY Change	91.36%	180.51%	94.86%
Cost Of Revenue	$21.84M	$18.51M	$10.05M
YoY Change	56.56%	84.18%	16.05%
Gross Profit	$41.06M	$42.33M	$11.64M
YoY Change	116.9%	263.66%	371.26%
Gross Profit Margin	65.28%	69.57%	53.66%
Selling, General & Admin	$41.15M	$35.24M	$21.59M
YoY Change	38.74%	63.21%	-9.66%
% of Gross Profit	100.22%	83.26%	185.51%
Research & Development	$25.88M	$24.57M	$14.25M
YoY Change	55.44%	72.38%	96.7%
% of Gross Profit	63.03%	58.04%	122.45%
Depreciation & Amortization	$3.450M	$2.500M	$1.700M
YoY Change	-43.44%	47.06%	54.55%
% of Gross Profit	8.4%	5.91%	14.6%
Operating Expenses	$67.02M	$59.81M	$35.85M
YoY Change	44.72%	66.86%	15.08%
Operating Profit	-$25.96M	-$17.48M	-$24.21M
YoY Change	-5.19%	-27.8%	-15.6%
Interest Expense	-$231.5M	$280.0K	$304.0K
YoY Change	-10432.59%	-7.89%	0.33%
% of Operating Profit
Other Income/Expense, Net	$234.8M	$179.0K	$43.00K
YoY Change	-261000.0%	316.28%	-116.17%
Pretax Income	-$22.60M	-$13.29M	-$23.51M
YoY Change	-10.46%	-43.46%	-17.78%
Income Tax	-$490.0K	-$202.0K	$0.00
% Of Pretax Income
Net Earnings	-$25.21M	-$13.09M	-$24.46M
YoY Change	0.36%	-46.48%	-14.45%
Net Earnings / Revenue	-40.08%	-21.51%	-112.75%
Basic Earnings Per Share
Diluted Earnings Per Share	-$268.1K	-$137.1K	-$292.7K
COMMON SHARES
Basic Shares Outstanding	93.91M shares	92.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$522.8M	$523.0M	$271.3M
YoY Change	24.77%	92.78%
Cash & Equivalents	$143.2M	$147.2M	$114.0M
Short-Term Investments	$379.6M	$375.8M	$157.4M
Other Short-Term Assets	$11.40M	$5.700M	$4.000M
YoY Change	119.23%	42.5%
Inventory	$15.18M	$14.76M	$7.075M
Prepaid Expenses
Receivables	$47.99M	$39.69M	$14.64M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$597.4M	$583.1M	$297.1M
YoY Change	27.37%	96.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$43.67M	$40.76M	$30.32M
YoY Change	40.85%	34.44%
Goodwill	$3.290M	$2.928M
YoY Change
Intangibles	$8.524M	$8.755M
YoY Change
Long-Term Investments	$268.8M	$302.6M	$3.000M
YoY Change	246.39%	9986.67%
Other Assets	$4.882M	$3.073M	$1.936M
YoY Change	138.61%	58.73%
Total Long-Term Assets	$365.2M	$365.3M	$47.52M
YoY Change	208.4%	668.7%
TOTAL ASSETS
Total Short-Term Assets	$597.4M	$583.1M	$297.1M
Total Long-Term Assets	$365.2M	$365.3M	$47.52M
Total Assets	$962.5M	$948.3M	$344.6M
YoY Change	63.86%	175.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.20M	$12.05M	$13.08M
YoY Change	52.2%	-7.85%
Accrued Expenses	$25.70M	$17.24M	$7.482M
YoY Change	258.08%	130.41%
Deferred Revenue	$12.28M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$100.0K	$100.0K
YoY Change		0.0%
Total Short-Term Liabilities	$72.73M	$67.82M	$32.05M
YoY Change	54.94%	111.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$100.0K	$100.0K
YoY Change	-100.0%	0.0%
Other Long-Term Liabilities	$1.672M	$1.220M	$206.0K
YoY Change	414.46%	492.23%
Total Long-Term Liabilities	$1.672M	$1.220M	$206.0K
YoY Change	414.46%	492.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$72.73M	$67.82M	$32.05M
Total Long-Term Liabilities	$1.672M	$1.220M	$206.0K
Total Liabilities	$114.5M	$86.44M	$47.46M
YoY Change	83.41%	82.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$352.8M	-$327.6M	-$255.7M
YoY Change	25.64%	28.13%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$798.4M	$815.4M	$255.2M
YoY Change
Total Liabilities & Shareholders Equity	$962.5M	$948.3M	$344.6M
YoY Change	63.86%	175.2%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$25.21M	-$13.09M	-$24.46M
YoY Change	0.36%	-46.48%	-14.45%
Depreciation, Depletion And Amortization	$3.450M	$2.500M	$1.700M
YoY Change	-43.44%	47.06%	54.55%
Cash From Operating Activities	-$30.34M	$1.350M	-$22.05M
YoY Change	14.32%	-106.12%	-17.54%
INVESTING ACTIVITIES
Capital Expenditures	-$7.020M	-$8.450M	-$5.910M
YoY Change	139.59%	42.98%	113.36%
Acquisitions
YoY Change
Other Investing Activities	$30.38M	-$27.28M	$30.37M
YoY Change	-115.6%	-189.83%	68.72%
Cash From Investing Activities	$23.36M	-$35.73M	$24.46M
YoY Change	-111.82%	-246.08%	60.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.070M	6.870M	800.0K
YoY Change	-98.77%	758.75%	-99.54%
NET CHANGE
Cash From Operating Activities	-30.34M	1.350M	-22.05M
Cash From Investing Activities	23.36M	-35.73M	24.46M
Cash From Financing Activities	3.070M	6.870M	800.0K
Net Change In Cash	-3.910M	-27.51M	3.210M
YoY Change	-114.96%	-957.01%	-98.04%
FREE CASH FLOW
Cash From Operating Activities	-$30.34M	$1.350M	-$22.05M
Capital Expenditures	-$7.020M	-$8.450M	-$5.910M
Free Cash Flow	-$23.32M	$9.800M	-$16.14M
YoY Change	-1.23%	-160.72%	-32.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Shell Company EntityShellCompany	false
	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.03
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Amendment Flag AmendmentFlag	false
	gh	Noncash Interest Expense Paid NoncashInterestExpensePaid	0	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93905925	shares
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q4	gh	Accrued Clinical Trialsand Studies AccruedClinicalTrialsandStudies	236000	USD
	dei	Entity Registrant Name EntityRegistrantName	Guardant Health, Inc.
CY2019Q3	gh	Accrued Clinical Trialsand Studies AccruedClinicalTrialsandStudies	1546000	USD
CY2018Q4	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	343000	USD
CY2019Q3	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	4210000	USD
CY2018Q4	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	7338000	USD
CY2019Q3	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	6780000	USD
CY2018Q4	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	381776000	USD
CY2019Q3	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	686458000	USD
CY2019Q3	gh	Contractual Obligation Future Minimum Payments Interest Includedin Payments ContractualObligationFutureMinimumPaymentsInterestIncludedinPayments	5023000	USD
CY2019Q3	gh	Contractual Obligation Future Minimum Payments Present Valueof Net Minimum Payments ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments	6780000	USD
CY2018Q3	gh	Costof Development Services CostofDevelopmentServices	380000	USD
	gh	Costof Development Services CostofDevelopmentServices	2041000	USD
CY2019Q3	gh	Costof Development Services CostofDevelopmentServices	1936000	USD
	gh	Costof Development Services CostofDevelopmentServices	6631000	USD
CY2018Q3	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	9671000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	27222000	USD
CY2019Q3	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	16578000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	42251000	USD
CY2018Q4	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	381858000	USD
CY2019Q3	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	685281000	USD
CY2018Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	814000	USD
CY2019Q3	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	2005000	USD
	gh	Increase Decrease In Capital Expenditures Incurred But Not Yet Paid IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid	1859000	USD
	gh	Increase Decrease In Capital Expenditures Incurred But Not Yet Paid IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid	6418000	USD
	gh	Noncash Interest Expense Paid NoncashInterestExpensePaid	10000	USD
	gh	Numberof Parties With Patent License Agreement NumberofPartiesWithPatentLicenseAgreement	4	party
	gh	Offering Costs Incurredbut Notyet Paid OfferingCostsIncurredbutNotyetPaid	4036000	USD
	gh	Offering Costs Incurredbut Notyet Paid OfferingCostsIncurredbutNotyetPaid	0	USD
CY2017Q1	gh	Payment In Connection Witha License Agreement PaymentInConnectionWithaLicenseAgreement	9700000	USD
	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	0	USD
	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	228000	USD
CY2018Q3	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	3394000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	7455000	USD
CY2019Q3	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	8701000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	28430000	USD
CY2018Q3	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	18298000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	50311000	USD
CY2019Q3	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	52147000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	123048000	USD
CY2018Q3	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.02
	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.02
CY2019Q3	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.03
CY2018Q4	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	508847	shares
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	5922	shares
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross	306958	shares
CY2018Q1	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	4000	USD
CY2018Q2	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	2000	USD
CY2018Q3	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	33000	USD
CY2019Q1	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	56000	USD
CY2019Q2	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
CY2019Q3	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	251000	USD
	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	330000	USD
	gh	Variable Interest Entity Fair Value Of Joint Venture Threshold For Share Purchase VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase	0.4
	gh	Variable Interest Entity Threshold Percentageof Fair Valuethatis No Less Than Internal Rateof Return VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn	0.2
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10642000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	12054000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35690000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39689000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40597000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-41000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1953000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1470000	USD
CY2019Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1884000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7081000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17239000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1791000	USD
CY2019Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2991000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	707000	USD
CY2019Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1622000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16634000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20830000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-83000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1109000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	764033000	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1141885000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1277000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1180000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1831000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3183000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3215000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5484000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	723000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1831000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4288000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5484000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11882000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-27000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	266000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	694000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	249000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	735000	USD
CY2018Q3	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	30000	USD
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	135000	USD
CY2019Q3	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	22000	USD
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	73000	USD
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	66205000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	66013000	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5761000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6664000	shares
CY2018Q4	us-gaap	Assets Assets	587403000	USD
CY2019Q3	us-gaap	Assets Assets	948334000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	468991000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	583062000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	235000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1288000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	317000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	111000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	422000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1065000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	97000	USD
CY2019Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	80000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	119000	USD
CY2019Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	57000	USD
CY2018Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	504000	USD
CY2019Q3	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	346000	USD
CY2019Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	171000	USD
CY2019Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	36000	USD
CY2019Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	108000	USD
CY2019Q3	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	34000	USD
CY2019Q3	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	137000	USD
CY2019Q3	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	27000	USD
CY2018Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	294000	USD
CY2019Q3	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	209000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140544000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147188000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72596000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114379000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140544000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147188000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	41783000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6644000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49249000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.03
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59940000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13025000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12067162	shares
CY2019Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8874689	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0000001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0000001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85832454	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93853390	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85832454	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93853390	shares
CY2018Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2019Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24297000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-23347000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-58990000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-13325000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-44549000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16100000	USD
CY2019Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	13100000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	14800000	USD
CY2019Q3	us-gaap	Contractual Obligation ContractualObligation	11803000	USD
CY2019Q3	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	5458000	USD
CY2019Q3	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	1637000	USD
CY2019Q3	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	1637000	USD
CY2019Q3	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	1365000	USD
CY2019Q3	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	1365000	USD
CY2019Q3	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	341000	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	45897000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	123321000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	78325000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	207887000	USD
CY2018Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	12986000	USD
CY2019Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	24604000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1235000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2019Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	745000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7844000	USD
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10564000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16138000	USD
CY2019Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13095000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	1700000	USD
	us-gaap	Depreciation Depreciation	4200000	USD
CY2019Q3	us-gaap	Depreciation Depreciation	2500000	USD
	us-gaap	Depreciation Depreciation	6800000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4967000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7963000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.94
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.87
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M21D
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y0M7D
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	17500000	USD
CY2019Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	26000000	USD
CY2018	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y0M0D
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7133000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8129000	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y3M0D
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7800000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7800000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7100000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23645000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16440000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42540000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	0	USD
CY2019Q3	us-gaap	Goodwill Goodwill	2928000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23508000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-58988000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13292000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-47124000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-202000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1383000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-205000	USD
	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-205000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1200000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	298000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3348000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	426000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1853000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-908000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	541000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6368000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-1086000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-3465000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	842000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3043000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2519000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	11618000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-212000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5624000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-97000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1043000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2483000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	453000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8755000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	304000	USD
	us-gaap	Interest Expense InterestExpense	952000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	280000	USD
	us-gaap	Interest Expense InterestExpense	860000	USD
	us-gaap	Interest Paid Net InterestPaidNet	67000	USD
	us-gaap	Interest Paid Net InterestPaidNet	860000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	9136000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	14760000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	958000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2932000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4286000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9870000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1200000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3400000	USD
CY2019Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1700000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	4600000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	62451000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	86438000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	587403000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	948334000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46944000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	67817000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	278417000	USD
CY2019Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	375768000	USD
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	77563000	USD
CY2019Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	302624000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42797000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	364227000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44660000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-340928000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45647000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16792000	USD
CY2018Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	950000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	950000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4700000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24458000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59941000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12790000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50441000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24205000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-65555000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17477000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56409000	USD
CY2019Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	60392000	USD
CY2019Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1467000	USD
CY2019Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9022000	USD
CY2019Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	8392000	USD
CY2019Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	8143000	USD
CY2019Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7292000	USD
CY2019Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	26076000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1720000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2981000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2046000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3073000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-27000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-27000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	137000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	542468000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	47000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-298000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	138000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	161000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	416000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1011000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-235000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1192000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	950000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	950000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-300000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	4700000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	188000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	28000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-282000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1055000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	206000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1220000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	43000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4587000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	179000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	275000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	172000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	221000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	811000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	7328000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2568000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48693000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17272000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11628000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5204000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5657000	USD
CY2018Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	249500000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	350432000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	41000000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	110625000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	223064000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2572000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9795000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-327599000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275892000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5118000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	38000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-13844000	USD
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-21639000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-23508000	USD
	us-gaap	Profit Loss ProfitLoss	-58991000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-21351000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	-11300000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-13090000	USD
	us-gaap	Profit Loss ProfitLoss	-45741000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47637000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61589000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31003000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40759000	USD
CY2018Q3	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-950000	USD
CY2019Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-4700000	USD
CY2019Q2	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-300000	USD
CY2019Q3	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	300000	USD
CY2018Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	41800000	USD
CY2019Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	46500000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	420000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	79000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14253000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34062000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24569000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60417000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280799000	USD
CY2018Q3	us-gaap	Revenues Revenues	21692000	USD
	us-gaap	Revenues Revenues	57766000	USD
CY2019Q3	us-gaap	Revenues Revenues	60848000	USD
	us-gaap	Revenues Revenues	151478000	USD
CY2018Q3	us-gaap	Royalty Expense RoyaltyExpense	319000	USD
	us-gaap	Royalty Expense RoyaltyExpense	936000	USD
CY2019Q3	us-gaap	Royalty Expense RoyaltyExpense	1400000	USD
	us-gaap	Royalty Expense RoyaltyExpense	3100000	USD
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13464000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	36351000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	18802000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	56048000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4288000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11882000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3556507	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2806659	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.52
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	352459	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	306958	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.45
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.65
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	55.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	53.02
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	250495000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	271740000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7588405	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4915418	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.58
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.23
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1851781	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.72
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.17
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	89.37
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	109974000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y5M12D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M15D
CY2019Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	71.00
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2627486	shares
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1933000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3185000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	349709000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1103000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	424000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	839000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	538000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4992000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4265000	USD
CY2018Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	172000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	308606000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	296848000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	276781000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	255187000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	483152000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	468134000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	815474000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	815396000	USD
CY2018Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.7378
CY2019Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	5700000	USD
CY2019Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	4900000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	48300000	USD
CY2019Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	45100000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	1200000	USD
CY2019Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	3000000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12582000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12300000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93303000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89452000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also invests in investment‑grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, estimation of potential credit losses on accounts receivable, the valuation of inventory, the fair value of assets acquired and liabilities assumed for business combinations, goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-19-013718-index-headers.html	Edgar Link	pending
0001628280-19-013718-index.html	Edgar Link	pending
0001628280-19-013718.txt	Edgar Link	pending
0001628280-19-013718-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-09302019x10q.htm	Edgar Link	pending
gh-0930x2019x10qxexhibit311.htm	Edgar Link	pending
gh-0930x2019x10qxexhibit312.htm	Edgar Link	pending
gh-0930x2019x10qxexhibit321.htm	Edgar Link	pending
gh-0930x2019x10qxexhibit322.htm	Edgar Link	pending
gh-20190930.xml	Edgar Link	completed
gh-20190930.xsd	Edgar Link	pending
gh-20190930_cal.xml	Edgar Link	unprocessable
gh-20190930_def.xml	Edgar Link	unprocessable
gh-20190930_lab.xml	Edgar Link	unprocessable
gh-20190930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2019 Q4 Form 10-Q Financial Statement

#000162828019013718 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2019 Q4 Form 10-Q Financial Statement

#000162828019013718 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh